Ascendis Pharma AS
(NAS:ASND)
$
137.5
-2.81 (-2%)
Market Cap: 8.39 Bil
Enterprise Value: 8.62 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 71/100 
Q2 2024 Ascendis Pharma A/S Earnings Call TranscriptSep 03, 2024$134.68 (-2.72%)Earnings- Q1 2024 Ascendis Pharma A/S Earnings Call TranscriptMay 02, 2024$141.1 (+0.06%)Earnings
- Q4 2023 Ascendis Pharma A/S Earnings Call TranscriptFeb 07, 2024$139.29 (-1.10%)Earnings
- Ascendis Pharma A/S at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Q3 2023 Ascendis Pharma A/S Earnings Call TranscriptNov 07, 2023$96.15 (+1.84%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Ascendis Pharma A/S at Citi BioPharma Conference TranscriptSep 07, 2023
- Q2 2023 Ascendis Pharma A/S Earnings Call TranscriptSep 05, 2023$99.74 (+1.50%)Earnings
- Ascendis Pharma A/S at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Ascendis Pharma A/S Oncology program update TranscriptMay 31, 2023
- Ascendis Pharma A/S at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Ascendis Pharma A/S Regulatory Update TranscriptMay 01, 2023
- Q1 2023 Ascendis Pharma A/S Earnings Call TranscriptApr 27, 2023$76.98 (+0.71%)Earnings
- Ascendis Pharma A/S Corporate Call TranscriptApr 03, 2023
- Q4 2022 Ascendis Pharma A/S Earnings Call TranscriptFeb 16, 2023$111.36 (-0.57%)Earnings
- Ascendis Pharma A/S at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Ascendis Pharma A/S Corporate Call TranscriptNov 14, 2022
- Q3 2022 Ascendis Pharma A/S Earnings Call TranscriptNov 02, 2022$113.94 (-2.37%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Ascendis Pharma A/S at Citi BioPharma Conference TranscriptSep 07, 2022
- Q2 2022 Ascendis Pharma A/S Earnings Call TranscriptAug 10, 2022$95.14 (+2.14%)Earnings
- Ascendis Pharma A/S at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Ascendis Pharma A/S Earnings Call TranscriptMay 11, 2022$78.08 (-5.52%)Earnings
- Ascendis Pharma A/S Announces Phase 3 PaTHway Trial Results Conference Call TranscriptMar 14, 2022
- Q4 2021 Ascendis Pharma A/S Earnings Call TranscriptMar 02, 2022$106.48 (-2.16%)Earnings
- Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Ascendis Pharma A/S R&D Update TranscriptDec 14, 2021
- Q3 2021 Ascendis Pharma A/S Earnings Call TranscriptNov 10, 2021$153.06 (-3.58%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Q2 2021 Ascendis Pharma A/S Earnings Call TranscriptAug 25, 2021$123.67 (+1.57%)Earnings
- Q1 2021 Ascendis Pharma A/S Earnings Call TranscriptMay 27, 2021$136.19 (+1.81%)Earnings
- Ascendis Pharma A/S Presents At Bank of America Securities 2021 Healthcare Conference (Virtual) TranscriptMay 11, 2021
- Full Year 2020 Ascendis Pharma A/S Earnings Call TranscriptMar 10, 2021$143.99 (-0.74%)Earnings
- Ascendis Pharma A/S at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 24, 2021
- Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Ascendis Pharma A/S - Special Call TranscriptNov 20, 2020
- Q3 2020 Ascendis Pharma A/S Earnings Call TranscriptNov 11, 2020$160 (-0.98%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptSep 29, 2020
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Q2 2020 Ascendis Pharma A/S Earnings Call TranscriptAug 27, 2020$137.82 (-1.18%)Earnings
- Ascendis Pharma A/S at Canaccord Genuity Growth Conference (Virtual) TranscriptAug 12, 2020
- Ascendis Pharma A/S at Wedbush PacGrow Healthcare Virtual Conference TranscriptAug 11, 2020
- Q1 2020 Ascendis Pharma A/S Earnings Call TranscriptMay 19, 2020$143.19 (+1.72%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptApr 19, 2020
- Q4 2019 Ascendis Pharma A/S Earnings Call TranscriptApr 01, 2020$113 (+0.35%)Earnings
- Ascendis Pharma A/S at Leerink Global Healthcare Conference TranscriptFeb 25, 2020
- Ascendis Pharma A/S at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Q3 2019 Ascendis Pharma A/S Earnings Call TranscriptNov 18, 2019$106.98 (-4.92%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Q2 2019 Ascendis Pharma A/S Earnings Call TranscriptAug 28, 2019$111.7 (-0.71%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptJun 26, 2019
- Q1 2019 Ascendis Pharma A/S Earnings and Business Update Call TranscriptMay 30, 2019
- Ascendis Pharma A/S at Bank of America Merrill Lynch Health Care Conference TranscriptMay 14, 2019
- Full Year 2018 Ascendis Pharma A/S Earnings Call TranscriptApr 03, 2019$116.9 (+3.29%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptMar 04, 2019
Ascendis Pharma A/S at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 04:20PM GMT
Release Date Price:
$92.93
(-0.34%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. We'll continue with our next session. I'm Paul Choi, and I cover the mid cap biotechnology sector here at Goldman Sachs. We're very pleased to have Ascendis here in our session here. Before we begin, to my left is CEO, Jan Mikkelsen; and to my far left, CFO, Scott Smith. I think Tim is going to read some forward language here before we begin the Q&A, but we'll let Tim go here.
Timothy J. Lee;S;Senior Director of IR
Ascendis Pharma A
/-
Comments during this discussion. Actual results made materially from those expressed or implied, and you should not place undue reliance on these statements. For information concerning the factors that can cause actual results to differ materially, please see the Risk Factors section of our most recent Annual Report on Form 20-F. And with that, let me turn it back to Paul.
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst
Thanks, Tim. So maybe what
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers